Table 3.

Hazard ratios [95% CIs] and P-values for OS at long-term follow-up in comparison to the control arm in the prespecified subgroup analyses

	Depatux-M + Temozolomide	Depatux-M Monotherapy
Relapse after TMZ ≤16 weeks >16 weeks	0.77 [0.51, 1.14], P = 0.19 0.46 [0.25, 0.88], P = 0.02	1.05 [0.72, 1.56], P = 0.79 0.76 [0.41, 1.40], P = 0.37
MGMT promoter Methylated Unmethylated	0.68 [0.39, 1.16], P = 0.16 0.63 [0.39, 1.03], P = 0.06	0.81 [0.49, 1.33], P = 0.40 1.21 [0.75, 1.97], P = 0.43
EGFRvIII mutation Present Not present	0.70 [0.43, 1.13], P = 0.14 0.66 [0.39, 1.13], P = 0.13	0.93 [0.57, 1.52], P = 0.77 1.05 [0.64, 1.73], P = 0.84